Table 8 EORTC QLQ-C30 scores with respect to tumor location, gender and symptoms of urgency and fecal soiling
| Â | Total | Tumor location in rectum | Gender | Urgency | Fecal soiling | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prox. | Mid. | Distal |  | F | M |  | (+) | (−) |  | (+) | (−) |  | ||
Median (min-max) | Median (min-max) | Pa | Median (min-max) | Pa | Median (min-max) | Pa | Median (min-max) | P a | ||||||
EORTC QLQ-C30 components | ||||||||||||||
 Global QoL/GHS | 58.3 (16.7–100) | 54.2 (33.3–66.7) | 58.3 (16.7–83.3) | 41.7 (16.7–100) | NA | 58.3 (33.3–100) | 41.7 (16.7–100) | 0.331 | 41.7 (16.7–100) | 70.8 (33.3–100) | 0.039 | 33.3 (16.7–66.7) | 66.7 (16.7–100) | 0.008 |
Functional scales | ||||||||||||||
 Physical function | 86.7 (0–100) | 73.3 (20–100) | 93.3 (40–100) | 83.3 (0–100) | NA | 90 (0–100) | 80 (40–100) | 1.00 | 80 (20–100) | 96.7 (0–100) | 0.345 | 80 (53.3–100) | 86.7 (0–100) | 0.943 |
 Role function | 91.7 (33.3–100) | 83.3 (33.3–100) | 100 (66.7–100) | 66.7 (33.3–100) | NA | 100 (33.3–100) | 83.3 (50–100) | 0.776 | 83.3 (33.3–100) | 100 (83.3–100) | 0.020 | 66.7 (50–100) | 100 (33.3–100) | 0.495 |
 Emotional function | 75 (25–100) | 70.8 (25–75) | 79.2 (33.3–100) | 75 (41.7–100) | NA | 75 (25–100) | 75 (33.3–100) | 0.571 | 70.8 (25–100) | 87.5 (50–100) | 0.136 | 66.7 (33.3–91.7) | 83.3 (25–100) | 0.032 |
 Cognitive function | 83.3 (50–100) | 83.4 (66.7–100) | 83.3 (50–100) | 91.7 (50–100) | NA | 83.3 (50–100) | 83.3 (50–100) | 0.561 | 83.3 (50–100) | 91.7 (50–100) | 0.491 | 100 (66.7–100) | 83.3 (25–100) | 0.554 |
 Social function | 66.7 (16.7–100) | 66.7 (50–83.3) | 66.7 (16.7–100) | 66.7 (33.3–100) | NA | 83.3 (33.3–100) | 50 (16.7–100) | 0.320 | 50 (16.7–100) | 83.3 (33.3–100) | 0.228 | 50 (33.3–83.3) | 75 (16.7–100) | 0.370 |
Symptom scales | ||||||||||||||
 Fatigue | 22.2 (11.1–77.8) | 55.6 (11–1) | 22.2 (11.1–44.4) | 22.2 (11.1–77.8) | NA | 22.2 (11.1–77.8) | 33.3 (11.1–55.6) | 0.683 | 33.3 (11.1–77.8) | 11.1 (11.1–55.6) | 0.162 | 11.1 (11.1–44.4) | 38.9 (11.1–77.8) | 0.043 |
 Nausea / vomiting | 0 (0–66.7) | 8.3 (0–33.3) | 0 (0–66.7) | 0 (0–66.7) | NA | 0 (0–66.7) | 0 (0–66.7) | 0.780 | 0 (0–66.7) | 0 (0–66.7) | 0.820 | 0 (0–66.7) | 0 (0–66.7) | 1.00 |
 Pain | 0 (0–100) | 16.7 (0–33.3) | 0 (0–100) | 0 (0–100) | NA | 8.3 (0–100) | 0 (0–100) | 0.591 | 0 (0–100) | 0 (0–100) | 0.936 | 0 (0–100) | 0 (0–100) | 0.776 |
 Dyspnea | 0 (0–33.3) | 0 (0–0) | 0 (0–0) | 0 (0–33.3) | NA | 0 (0–33.3) | 0 (0–33.3) | 0.780 | 0 (0–100) | 0 (0–33.3) | 0.817 | 0 (0–33.3) | 0 (0–33.3) | 0.166 |
 Sleep disturbance | 0 (0–100) | 66.7 (0–100) | 33.3 (0–100) | 0 (0–100) | NA | 0 (0–100) | 33.3 (0–100) | 0.505 | 33.3 (0–100) | 0 (0–66.7) | 0.185 | 33.3 (0–100) | 0 (0–100) | 0.522 |
 Loss of appetite | 0 (0–100) | 16.7 (0–100) | 0 (0–33.3) | 0 (0–66.7) | NA | 0 (0–100) | 0 (0–33.3) | 0.621 | 0 (0–100) | 0 (0–66.7) | 0.896 | 0 (0–33.3) | 0 (0–100) | 0.256 |
 Constipation | 0 (0–100) | 33.3 (0–100) | 0 (0–33.3) | 0 (0–100) | NA | 0 (0–100) | 0 (0–33.3) | 0.747 | 0 (0–100) | 0 (0–100) | 0.436 | 0 (0–33.3) | 0 (0–100) | 0.278 |
 Diarrhea | 0 (0–100) | 16.7 (0–33.3) | 0 (0–100) | 0 (0–100) | NA | 0 (0–100) | 0 (0–100) | 0.813 | 0 (0–100) | 33.3 (0–100) | 0.126 | 0 (0–66.7) | 0 (0–100) | 0.701 |
 Financial impact | 0 (0–100) | 33.3 (0–100) | 0 (0–100) | 50 (0–100) | NA | 16.7 (0–100) | 33.3 (0.0–100) | 0.747 | 33.3 (0–100) | 0 (0–100) | 0.423 | 66.7 (0–100) | 0 (0–100) | 0.234 |